Objectives: To investigate associations of chronic inflammatory infiltrate (CII) with prostate cancer (PCa) risk and the number of positive cores in patients elected to a first set of biopsies. Materials and Methods: Excluding criteria were as follows: active surveillance, prostate specific antigen (PSA) ≥ 30 ng/l, re-biopsies, incidental PCa, less than 14 cores, metastases, or 5-alpha reductase inhibitors. The cohort study was classified as negative (control group) and positive cores between 1 and 2 or > 2. Results: The cohort included 421 cases who did not meet the exclusion criteria. PCa was detected in 192 cases (45.6%) of which the number of positive cores was between 1 and 2 in 77 (40.1%) cases. The median PSA was 6.05 ng/ml (range 0.3-29 ng/ml). Linear regression models showed that CII was an independent predictor inversely associated with the risk of PCa. Multinomial logistic regression models showed that CII was an independent factor that was inversely associated with PCa risk in cases with positive cores between 1 and 2 (OR = 0.338; p = 0.004) or more than 2 (OR = 0.076; p < 0.0001) when compared to the control group. Conclusion: In a cohort of men undergoing the first biopsy set after prostate assessment, the presence of CII in the biopsy core was an independent factor inversely associated with PCa risk as well as with the number of positive biopsy cores (tumor extension). Clinically, the detection of CII in negative biopsy cores might reduce the risk of PCa in repeat biopsies as well as the probability of detecting multiple positive cores.

1.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
2.
Coussens LM, Werb Z: Inflammation and cancer. Nature 2002;420:860-867.
3.
Kuraishy A, Karin M, Grivennikov SI: Tumor promotion via injury- and death-induced inflammation. Immunity 2011;35:467-477.
4.
Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature 2008;454:436-444.
5.
Selman SH: The McNeal prostate: a review. Urology 2011;78:1224-1228.
6.
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F: The role of chronic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-441.
7.
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106-117.
8.
Krieger JN, Nyberg L Jr, Nickel JC: NIH consensus definition and classification of prostatitis. JAMA 1999;282:236-237.
9.
Porcaro AB, Rubilotta E, Petrozziello A, Ghimenton C, Migliorini F, Zecchini Antoniolli S, La Cola V, Monaco C, Curti P, Cavalleri S, Pianon R, Artibani W: Chronic inflammation of the prostate type IV with respect to risk of prostate cancer. Arch Ital Urol Androl 2014;86:208-211.
10.
Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V, Martignoni G, Brunelli M, Cerruto MA, Curti P, Cavalleri S, Artibani W: Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. Urol Int 2015;94:270-285.
11.
Blumenfeld W, Tucci S, Narayan P: Incidental lymphocytic prostatitis. Selective involvement with non malignant glands. Am J Surg Pathol 1992;16:975-981.
12.
Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW: Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for radical difference in prostate specific antigen. J Urol 2000;163:131-136.
13.
Gerstenbluth RE, Seftel AD, MacLennan GT, Rao RN, Corty EW, Ferguson K, Resnick MI: Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167:2267-2270.
14.
Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, Mottet N: High-grade inflammation in prostate as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology 1999;54:467-472.
15.
Karakiewicz PI, Benayoun S, Begin LR, Duclos A, Valiquette L, McCormack M, Bénard F, Saad F, Perrotte P: Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract 2007;61:425-430.
16.
Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, Freedland SJ: Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer 2014;120:190-196.
17.
Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ: Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: results from the REDUCE study. Prostate 2015;75:1492-1498.
18.
Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ: Prostatitis as a risk factor for prostate cancer. Epidemiology 2004;15:93-99.
19.
Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR: Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2010;20:2280-2287.
20.
Engelhardt PF, Brustmann H, Seklehner S, Riedl CR: Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scand J Urol 2013;47:230-235.
21.
Sfanos KS, Hempel HA, De Marzo AM: The role of inflammation in prostate cancer. Adv Exp Med Biol 2014;816:153-181.
22.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-269.
23.
Sfanos KS, De Marzo AM: Prostate cancer and inflammation: the evidence. Histopathology 2012;60:199-215.
24.
Strasner A, Karin M: Immune infiltration and prostate cancer. Front Oncol 2015;5:128.
25.
Thun MJ, Henley SJ, Patrono C: Nonsteroidal anti-inflammatory drugs as anticancers agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
26.
Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ: A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-980.
27.
Pruthi RS, Derksen JE, Moore D: A pilot study of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004;93:275-278.
28.
Di Silverio F, Sciarra A, Gentile V: Etericoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. Urology 2008;71:947-951.
29.
Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG: Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009;9:419-426.
30.
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis. J Nat Cancer Inst 1993;85:307-311.
31.
Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1462-1466.
32.
Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S: Association between coronary heart disease and cancer of the breast, prostate and colon. Cancer Epidemiol Biomarkers Prev 1998;7:869-873.
33.
Drake CG: Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10:580-593.
34.
Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P: Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 2011;31:813-828.
35.
Hoekx L, Jeuris W, Van Marck E, Wyndaele JJ: Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation. Acta Urol Belg 1998;66:1-2.
36.
Sindhwani P, Wilson CM: Prostatis and serum prostate-specific antigen. Curr Urol Rep 2005;6:307-312.
37.
Hochreiter WW: The issue of elevated prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. Andrologia 2008;40:130-133.
38.
Roobol MJ, Schroder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Vickers AJ, Lilja H, Steyerberg EW: Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 2012;30:149-155.
39.
Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N: Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 2007;69:103-107.
40.
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147:815-816.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.